posted on 01 Jul 2019
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).
THR-149 has been developed in partnership with Bicycle Therapeutics (Nasdaq: BCYC).
The Phase 1 open-label, multicenter (US), non-randomized trial evaluated the safety of a single intravitreal (IVT) injection of THR-149, a novel PKal inhibitor, at 3 ascending dose levels in 12 subjects with visual impairment due to center-involved DME (CI-DME) (NCT03511898).
Topline data from the trial show that THR-149 is well-tolerated and safe. No dose-limiting toxicities nor drug-related serious adverse events were reported at any of the dosages evaluated in the study.
For more details, please see the article here
PerimeterX, the leading provider of application security solutions that keep web businesses safe in the digital world, today announced the availability of PerimeterX Bot Defender on Google Cloud Platform Marketplace (GCP Marketplace), providing customers with the ability to protect web and mobile applications and APIs from automated attacks and to safeguard their consumers’ digital experience.
Cymulate today announced that it has raised $15 million in venture capital as the cybersecurity company continues international expansion of its cloud-based platform.
PerimeterX, the leading provider of application security solutions that keep web businesses safe in the complex digital world, today announced that it has been named the winner of the “Overall CyberSecurity Startup of the Year” award in the 2019 CyberSecurity Breakthrough Awards program from CyberSecurity Breakthrough, a leading independent market intelligence organization that recognizes the top companies, technologies and products in the global information security market today.